<DOC>
	<DOCNO>NCT00457418</DOCNO>
	<brief_summary>The purpose study establish pharmacokinetics PEG-Intron , administer dose 6 μg/kg/week 8 week ( induction treatment ) , follow dose 3 μg/kg/week 252 week ( maintenance treatment ) , patient high risk melanoma .</brief_summary>
	<brief_title>High-Dose PEG-Intron Pharmacokinetic Study Patients With Melanoma ( Study P04831 AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects least 18 year age , either sex , race . Cytologically histologicallyconfirmed melanoma , arise cutaneous unknown site origin , Stages IIB , IIC , IIIA , IIIB , IIIC accord American Joint Committee Cancer ( AJCC ) 2001 guideline . Adequate hepatic , renal bone marrow function within 4 week prior initiation study treatment . Subjects present synchronous primary regional melanoma must adequate surgical margin surround primary lesion . Full lymphadenectomy must perform within 90 day prior initiation study treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Give informed consent accord International Conference Harmonisation Good Clinical Practice ( ICHGCP ) national/local policy . Be able adhere dose visit schedule . Female subject childbearing potential must use medically accept method birth control prior Screening agree continue use study surgically sterilize . Female subject childbearing potential must negative serum pregnancy test Screening . Female subject pregnant , intend become pregnant , breastfeed . Previous treatment interferon alpha , chemotherapy immunotherapy melanoma . Ocular melanoma , melanoma mucous membrane . Evidence distant nonregional lymph node metastasis . Intransit melanoma , even lesion resect . Disease completely surgically resect . Lack recovery recent surgery . Prior malignancy within past 5 year , except surgically cure squamous cell carcinoma skin , successfully resect early stage cutaneous melanoma , cervical carcinoma situ . Severe cardiovascular disease . Thyroid dysfunction responsive therapy . Uncontrolled diabetes mellitus ( opinion investigator ) . Active autoimmune disease . Active and/or uncontrolled infection . History seropositivity human immunodeficiency virus ( HIV ) . Preexisting psychiatric condition . Clinical diagnosis substance abuse one follow drug within follow timeframes ( exclude time spend detoxification , hospitalization incarceration ) : Alcohol , intravenous drug use , inhalational , psychotropics , narcotic , cocaine , prescription overthecounter drug : within 1 year Screening visit . Methadone , buprenorphine hydrochloride ( HCl ) , and/or butorphanol tartrate : within 1 year Screening visit , unless subject drug screen negative ( nonnarcotic ) drug document past year repeat negative within 2 month Screening visit . Multidrug abuse ( 2 substance 16a 16b ) : within 3 year Screening visit . Marijuana : If historic use deem excessive principal investigator ( medically qualify individual ) , interfere subject 's life , subject eligible screen . If marijuana use deem excessive principal investigator interfere life , subject must discontinue current use marijuana prior entry study . Medical condition require chronic systemic corticosteroid . Known allergy drug substance excipients PEGIntron formulation . Any situation condition , opinion investigator , may interfere optimal participation study . Use investigational drug within 30 day study entry . Participation clinical study investigational treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>